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Cdk2 promotes DNA replication and is a promising
cancer therapeutic target, but its functions appear
redundant with Cdk1, an essential Cdk affected by
most Cdk2 inhibitors. Here, we present an integrated
multidisciplinary approach to address Cdk redun-
dancy. Mathematical modeling of enzymology data
predicted conditions allowing selective chemical
Cdk2 inhibition. Together with experiments in Xeno-
pus egg extracts, this supports a rate-limiting role
for Cdk2 in DNA replication. To confirm this we
designed inhibitor-resistant (ir)-Cdk2 mutants using
a novel bioinformatics approach. Bypassing inhibi-
tion with ir-Cdk2 or with Cdk1 shows that Cdk2
is rate-limiting for replication in this system because
Cdk1 is insufficiently active. Additionally, crystal
structures and kinetics reveal alternative binding
modes of Cdk1-selective and Cdk2-selective inhibi-
tors and mechanisms of Cdk2 inhibitor resistance.
Our approach thus provides insight into structure,
functions, and biochemistry of a cyclin-dependent
kinase.
INTRODUCTION
Protein kinases are an important new class of targets for spe-
cific pharmacological inhibition in therapy, especially for cancers
(Johnson, 2009). Cyclin-dependent kinases (Cdks) are con-
served kinases that play critical roles in the cell cycle, transcrip-
tion, translation, and other processes, and their upregulation is
involved in many pathologies. Over a hundred small-molecule
Cdk inhibitors have been developed, at least ten of which are
currently in clinical trials as anticancer drugs (Bettayeb et al.,
2007; Malumbres et al., 2008), and these are also important tools
for studying Cdk functions. However, all inhibitors currently in1028 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 Eltherapeutic use, and most of those under development, target
multiple kinases. To design effective therapeutic strategies, it
is important to understand which targets are responsible for
the effects of an inhibitor in a given context.
This understanding is hampered by the fact that in vivo, Cdks
appear to be redundant. From fission yeast to mammals, even
though multiple Cdk-cyclin complexes drive cell-cycle progres-
sion, a single one may suffice for promoting both replication and
mitosis (Coudreuse and Nurse, 2010; Fisher and Nurse, 1996;
Santamarı´a et al., 2007). These results support a ‘‘quantitative
model’’ of Cdk control over the cell cycle (Fisher and Nurse,
1996; Coudreuse and Nurse, 2010), whereby the Cdk activity
level determines the stage of the cell cycle, as opposed to a
‘‘qualitative model’’ in which different Cdk-cyclin complexes
are required to promote separate cell-cycle events. In most
cell systems, onset of S-phase is tightly linked to a restriction
point in G1 that governs transcription. Both transition through
the restriction point and activation of replication origins require
Cdk activity, making it difficult to study specific control of DNA
replication by Cdk activity. Xenopus egg extracts recapitulate
embryonic cell cycles that have neither a G1 restriction point
nor transcription requirement, making them ideal for studying
the control of S-phase by Cdk activity. Although depletion exper-
iments in Xenopus egg extracts originally indicated that Cdk2,
but not Cdk1, promotes DNA replication (Fang and Newport,
1991), using single molecule DNA combing to study replication
origin firing, we found that Cdk1 and Cdk2 both activate replica-
tion origins, although only Cdk2 is effective at promoting activa-
tion of origin clusters and is therefore rate-limiting for replication
in this system (Krasinska et al., 2008). The reason for this is
unknown. Yet, genetic knockdown or deletion of Cdk2 in other
systems does not affect DNA replication, apparently because
of compensation by Cdk1 (Aleem et al., 2005; Hochegger
et al., 2007; Tetsu and McCormick, 2003). However, the conclu-
sion that Cdks are redundant might depend on the experimental
approach used. Recently, chemical genetics revealed essen-
tial cell-cycle functions for Cdk2 in cultured human cells that
are not observed when depletions are used (Merrick et al.,
2011). At present, it is not clear whether this requirement is forsevier Ltd All rights reserved
Chemistry & Biology
Cdk2 Chemical Biologypromoting passage through the restriction point or for directly
promoting DNA replication, but it is clearly important to address
Cdk2 function by methods that do not rely on knockdowns or
knockouts. Chemical kinase inhibition is one such approach,
because the physiological levels of the kinase studied are main-
tained. However, to date, lack of strict specificity is a major
caveat of kinase inhibitors, which usually inhibit multiple kinases
(Bain et al., 2007; Karaman et al., 2008), confounding interpreta-
tions of experiments using them in vivo.
Understanding the role of Cdk2 is important not only for under-
standing the cell cycle but also because Cdk2 is a promising
cancer therapeutic target. In mice, cdk2 knockout embryo fibro-
blasts (MEFs) proliferate much less well than wild-type MEFs
and are resistant to immortalization and transformation (Berthet
et al., 2003; Ortega et al., 2003). Some cancers are inherently
Cdk2-dependent (Du et al., 2004), and others acquire Cdk2-
dependency as a mechanism of clinical resistance to a primary
treatment (Scaltriti et al., 2011). Similar results for other Cdks
suggest that selective therapeutic targeting of cancer cells by
inhibiting specific Cdks might be possible (Malumbres et al.,
2008). To better understand the differences in ability of Cdk1
and Cdk2 in promoting DNA replication, we surmised that quan-
titative analysis of their kinase activity by specific chemical
inhibition would complement our understanding from depletion
experiments. Therefore, in this study, we first undertake a kinetic
characterization of Cdk inhibitors and develop a simple mathe-
matical model of inhibition of multiple Cdks in a physiological
system, which agrees well with experimental results using dif-
ferent Cdk inhibitors. This suggests that Cdk2 indeed has rate-
limiting functions in DNA replication in Xenopus egg extracts
but that Cdk1 nevertheless also independently promotes DNA
replication.
To confirm these results and to analyze the quantitative contri-
butions of each kinase to DNA replication, we wanted to per-
form complementation experiments to restore kinase activity in
the presence of inhibitors. Here, we describe a simple bioinfor-
matics approach to design inhibitor resistance that we validate
by generating inhibitor-resistant (ir-)Cdk2 mutants. We then
used ir-Cdk2 in combination with inhibitors and mathematical
modeling to examine how Cdk1 and Cdk2 activities control
DNA replication. The results suggest that the most important
parameter is total Cdk activity. Finally, because clinical resis-
tance due to spontaneous mutations in the inhibitor-targeted
kinase is a serious problem in cancer therapy, yet very little is
known about mechanistic effects of resistance-causing muta-
tions in kinases, we further analyzed the kinetics and crystal
structures of ir-Cdk2, as well as structures of wild-type Cdk2
with inhibitors of different specificity. This comparison revealed
important mechanistic determinants of Cdk inhibitor sensitivity
and resistance.
RESULTS
Enzymology: Cyclin Binding and ATP Affinities Strongly
Influence Cdk Inhibitor Selectivity
Initiating DNA replication commits a cell to dividing and requires
Cdk activity, but the respective importance of Cdk1 and Cdk2 is
still not clear, as either can promote replication when the other is
absent. Pharmacological inhibition of Cdk2, rather than deple-Chemistry & Biology 19, 1028–tion or knockdown, might yield a different result and could
perhaps allow us to determine the importance of the level of
kinase activity. In order to model conditions allowing specific
Cdk2 inhibition within a complex physiological system, we first
undertook a comprehensive study of Cdk kinetics in vitro. We
used three recently developed ATP-competitive inhibitors (Fig-
ure S1, available online) that have high affinity and, apparently,
specificity for Cdks. NU6102, a substituted cyclohexylmethyl
guanine, has low nanomolar inhibitor constant (Ki) for Cdk1
and Cdk2 (Davies et al., 2002). Inhibition factor of the initial
velocity (v) of an enzyme obeying Michaelis-Menten kinetics
with a competitive inhibitor:
v
vi
= 1+
½I
Ki

1+
½S
Km
; (Equation 1)
with vi as inhibited velocity, [S] as substrate, [I] as inhibitor, Ki
as inhibitor constant, and Km as Michaelis constant. Purvalanol
A, a trisubstituted roscovitine analog, has a similar low nano-
molar Ki for Cdk1-cyclin B, with reported selectivity for Cdk1
over Cdk2 and Cdk4 (Gray et al., 1998). And, the quinolinyl thia-
zolinone, RO-3306, is reportedly selective for Cdk1 (Vassilev
et al., 2006). Although inhibitors are often deemed specific for
a particular kinase when the inhibitor constant, Ki is lower than
for other kinases, such assessments may be inaccurate if
affinity for the natural ligand (usually ATP) is not considered.
Rearranging the Michaelis-Menten equation with competitive
inhibition to estimate the inhibition factor v=vi of an enzyme
under saturating conditions ([I]>>[Enzyme]) (Equation 1), it can
be seen that inhibition will tend to be strong if inhibitor concen-
tration [I] is high with respect to the Ki and also if the Km for
ATP is high with respect to ATP concentration [S]. With equal
Ki, increasing ATP affinity (lower Km) will reduce inhibition and
vice versa. As such, the absolute value of Ki for a given kinase
complex is less instructive than the Km/Ki ratio: the higher the
ratio, the better the inhibitor competes with ATP. Cdk4 appar-
ently has a much lower ATP affinity than Cdk2 (Konstantinidis
et al., 1998), suggesting that Cdk4 should be sensitive to in-
hibitors deemed to be selective for Cdk2 on the basis of respec-
tive Ki values. Moreover, in the Cdk4-cyclin D crystal structures
the conserved C-helix is not repositioned upon cyclin binding
to optimize catalysis, as in other Cdk-cyclin structures (Echalier
et al., 2010), hinting that cyclin interactions affect binding
of Cdks to both ATP and inhibitors, although this has not
yet been well documented. With these points in mind, we first
determined the ATP affinities of different human Cdk-cyclin
complexes (Table 1). The results reveal that this parameter is
of particular importance for Cdks, whose Km (ATP) varies widely
within the subfamily and also depends on the cyclin subunit.
Cyclin E reduces ATP affinity of both Cdk1 and Cdk2 3-fold
when compared to cyclins A or B. Second, Cdk1 and Cdk2
have similar Km (ATP) when complexed with the same cyclins.
Therefore, although Cdk1 has not been crystallized, the topolo-
gy of its ATP binding site is likely to be similar to that of Cdk2
(which has 65% overall sequence identity with Cdk1). Third,
Cdk4 has only millimolar affinity for ATP, as reported (Konstan-
tinidis et al., 1998), as does Cdk3; therefore, in physiological
conditions, both should be sensitive in vivo to inhibitors of
micromolar affinity.1040, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1029
Table 1. ATP Affinity of Cdk Complexes Depends on the Cyclin Subunit and Influences Inhibitor Selectivity
Complex Km (ATP)/mM
Ki and Km/Ki Ratio
NU6102 Purvalanol A RO-3306
Ki Km/Ki Ki Km/Ki Ki Km/Ki
CDK1-cyclin A 52 ± 13 1.6 ± 0.3 32 0.21 ± 0.04 250 0.12 ± 0.02 430
CDK1-cyclin B 34 ± 17 0.8 ± 0.4 41 0.15 ± 0.06 230 0.07 ± 0.01 520
CDK1-cyclin E 159 ± 35 4.0 ± 1.8 40 0.33 ± 0.09 480 0.24 ± 0.10 660
CDK2-cyclin A 46 ± 3 0.08 ± 0.04 550 0.18 ± 0.11 270 0.89 ± 0.26 52
CDK2-cyclin E 225 ± 103 0.39 ± 0.11 580 0.21 ± 0.08 1,050 1.32 ± 0.60 170
CDK3-cyclin E 779 ± 373 0.02 ± 0.01 48,700 0.01 ± 0.008 84,000 0.03 ± 0.02 22,600
CDK4-cyclin D 5,130 ± 1,700 0.25 ± 0.03 20,500 1.63 ± 0.15 3,150 197 ± 143 26
Purified recombinant kinases were used in in vitro assays with variable ATP concentrations under identical conditions to determine the Michaelis
constant, Km. The Km [ATP]/Ki [inhibitor] ratio is proportional to the relative affinity of kinase for inhibitor with respect to ATP. Because the Km varies,
this value better represents the selectivity of the inhibitor than the Ki. See structures of inhibitors in Figure S1A.
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Cdk2 Chemical BiologyWe then re-evaluated specificity of NU6102, RO-3306, and
Purvalanol A for different Cdk-cyclin complexes (Table 1). These
results show, first, that NU6102 inhibits Cdk2-cyclin E and Cdk2-
cyclin A equally well, despite the lower Ki for the latter. Second,
NU6102 has clear in vitro selectivity for Cdk2 over Cdk1, irre-
spective of the cyclin associated. Although not seen in the orig-
inal study (Davies et al., 2002), this selectivity agrees with
another report and also applies for Xenopus homologs of these
kinases (Heady et al., 2006; Krasinska et al., 2008). As previously
published (Vassilev et al., 2006), RO-3306 is selective in vitro
for Cdk1 when compared with Cdk2, although it moderately
inhibits Cdk2-cyclin E, and it does not inhibit Cdk4. But, Purva-
lanol A is not selective for Cdk1, and, along with NU6102, it is
an effective inhibitor of Cdk2, Cdk3, and Cdk4. These results
suggest that it might be possible to assess whether Cdk2 and
Cdk1 are truly redundant in promoting DNA replication, without
performing depletions, by comparing effects of these three in-
hibitors on replication.
Combining Mathematical Modeling and Experiments in
Xenopus Egg Extracts Suggests a Rate-Limiting Role for
Cdk2 in DNA Replication
Using kinetics data (Table 1), we mathematically modeled
activity of human Cdk1 and Cdk2 complexes using different
inhibitors (Figure 1A). The results show that achieving selective
inhibition of Cdk1 or Cdk2 in a complex system is feasible,
although both will always be affected to some extent. At 10 mM
NU6102, Cdk1 should retain about 75% of activity compared
to 15% for Cdk2. The corresponding values would be 15%
and 50% for RO-3306 and 30%–40% versus 15%–20% for Pur-
valanol A, respectively. At 100 mM NU6102, Cdk1 activity would
be around 20% versus 2% for Cdk2, whereas with RO-3306
these values would be inverted. We next analyzed dose-depen-
dency of inhibition of DNA replication in Xenopus egg extracts
with different Cdk inhibitors (Figure 1B). We have not been able
to detect any Cdk3 or Cdk4 expression in this system. Using
depletion approaches, we previously found that replication
depends mainly on Cdk2 activity, with Cdk1 able to contribute
to a small but significant extent (Krasinska et al., 2008). In agree-
ment with inhibition kinetics of the human homologs, 100 mM
Purvalanol A, which efficiently inhibits both Cdk1 and Cdk2, is
most effective at inhibiting replication, while RO-3306 is least1030 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 Eleffective (Figures 1B and S1B). The apparent rate-limiting nature
of Cdk2 for replication in this system might be due to qualitative
differences between Cdk2-cyclin E and Cdk1-cyclin A com-
plexes or simply the differences in their kinase activities. Indeed,
we estimated that Cdk2 is about 3-fold more active than Cdk1 in
interphase egg extracts (Krasinska et al., 2008). Next, to more
precisely model NU6102 action in Xenopus egg extracts, we
generated recombinant active complexes of Xenopus Cdk2
and Cdk1 with Xenopus cyclins E and A, respectively, and eval-
uated their sensitivity to NU6102. A stable recombinant Xenopus
Cdk1 complex was achieved by making a fusion protein with
cyclin A (see the Supplemental Experimental Procedures). The
Xenopus Cdk1-cyclin A complex had a Ki [NU6102] of 20.5 mM
compared to 0.51 mM for Xenopus Cdk2-cyclin E, showing
that the difference in NU6102 sensitivities is conserved across
species. The results were used to model activity of Xenopus
Cdk1 and Cdk2 as a function of inhibitor concentration (Fig-
ure 1C). We then correlated predictions of Cdk1 and Cdk2 activ-
ities with replication efficiencies in experiments using different
NU6102 concentrations in egg extracts (Figures 1C, 1D, and
1E). For example, at 1 mMNU6102, Cdk1 should be 99% active,
Cdk2 about 80% active (Figure 1C), and replication rates are
about 80% of normal (Figure 1D). Replication rates bottom out
at about 40% using 100–200 mM NU6102, where total Cdk1 +
Cdk2 activity should be about 10% of control levels. At these
concentrations, Cdk2 should be less than 1% active, but Cdk1
should retain 40%–50% activity, that is, Cdk2 is selectively in-
hibited. Assuming that the sole effect of NU6102 on DNA replica-
tion is via inhibition of Cdk activities, we can combine modeling
and experimental results and plot Cdk activities against DNA
replication (Figure 1E). This representation of the data suggests
that DNA replication has a sigmoidal response with respect to
Cdk2 activity and is insensitive to large changes in Cdk2 activity.
At lower Cdk activity levels, the correlation is more or less linear
between replication and Cdk2 activity. However, because Cdk2
activity is the major contributor to total Cdk activity at lower
NU6102 levels, it is possible that the only significant variable is
total Cdk activity rather than Cdk2 activity, which would provide
further evidence for the quantitative model. If so, restoration of
Cdk2 activity in the presence of NU6102 should reinstate normal
DNA replication levels, and increasing Cdk1 activity while main-
taining Cdk2 inhibited might also have the same effect. Cdk1 issevier Ltd All rights reserved
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Figure 1. A Chemical Biology Approach
Suggests a Rate-Limiting Role for Cdk2 in
DNA Replication
(A) Modeling physiological inhibition of different
Cdk complexes by NU6102, RO-3306, and Pur-
valanol A using Michaelis-Menten kinetics and the
parameters determined in Table 1.
(B) Dose-dependency of pharmacological inhibi-
tion of DNA replication by NU6102, RO-3306,
and Purvalanol A in Xenopus egg extracts.
Interphase extracts were incubated with demem-
branated sperm nuclei and inhibitors at indicated
concentrations or DMSO control (0), and the
percentage of input DNA replicated was quantified
using radioactive 33P-dCTP incorporation at
90 min.
(C) Modeling kinase activities of Xenopus Cdk2
and Cdk1 in extract conditions. Total and indi-
vidual kinase activities in extracts predicted at
different concentrations of NU6102, where Cdk2
activity is three times that of Cdk1without inhibitor.
Values used were measured for recombinant
complexes: Cdk2-cyclin E: Km [ATP] = 158 mM,
Ki [NU6102] = 0.51 mM; Cdk1-cyclin A: Km [ATP] =
100 mM, Ki [NU6102] = 20.5 mM.
(D) Time course of dose-dependency of DNA
replication on NU6102. Error bars show SEM. (n =
14 [control], 2 [1 mM], 3 [10 mM], 7 [50 mM], 10
[100 mM], and 6 [200 mM]).
(E) Combining modeling and experiment: repre-
sentation of DNA replication from (D) as a function
of the Cdk activities predicted from (C) at the same
NU6102 concentrations. See also Figure S1.
Chemistry & Biology
Cdk2 Chemical Biologynaturally resistant to NU6102, potentially allowing comple-
mentation. We surmised that restoring Cdk2 activity might be
achieved using an inhibitor-resistant Cdk2 mutant, as depicted
in Figure 2A.
A Systems-Based Method to Design Inhibitor-
Resistance into Kinases
Inhibitor resistance has not yet been described for Cdks, so
we sought to design it de novo. Generation of inhibitor resis-
tance in protein kinases by mutation or selection using genetic
screens has been achieved for various kinases, including p38,
c-Abl, Aurora A, Aurora B, Plk1, c-Src, PAK5, Phkg, CK1d, and
haspin (Azam et al., 2003; Balzano et al., 2011; Bradeen et al.,
2006; Eyers et al., 1998; Girdler et al., 2008; Gum et al., 1998;
Scutt et al., 2009), implying that inhibitor resistance might
be achievable for any protein kinase. Bioinformatics analysisChemistry & Biology 19, 1028–1040, August 24, 2012 ªhas shown that kinases have similar
amino acids at residues contributing
the most binding energy in complexes
with high-affinity inhibitors (Sheinerman
et al., 2005). This yields a ligand-binding
signature of 10 to 20 amino acids of the
kinase domain. We hypothesized that
aligning this signature for a particular
kinase-inhibitor complex with related
protein kinases that are naturally in-
sensitive to the inhibitor should allowprediction of substitutions reducing inhibitor affinity but retain-
ing kinase activity. We first evaluated this idea using the
c-Abl tyrosine kinase, in which many mutations that cause
resistance to Imatinib are known (Azam et al., 2003; Bradeen
et al., 2006). The ligand signature for this complex comprises
16 residues (Sheinerman et al., 2005), of which eight are essen-
tially invariant in all kinases (Figures 2B and 2C). Residues fre-
quently substituted in insensitive kinases include V289, M290,
V299, I293, T315, and I360, which would thus be good candi-
dates for mutation to generate resistant kinases. Indeed, thre-
onine-315, the gatekeeper residue, is often mutated in Imati-
nib-resistant cancers. Of the five other positions, three were
found substituted in a screen to select for Imatinib-resistant
Abl mutants, whereas none were recovered with mutations in
the highly conserved residues. This analysis shows that align-
ing ligand signatures against insensitive kinases works well to2012 Elsevier Ltd All rights reserved 1031
BC
D
E
A Figure 2. A Systems-Based Approach to
Design Inhibitor Resistance
(A) Inhibitor-resistant kinases as tools for analyzing
physiological functions of individual kinases. An
inhibitor may affect not only the kinase of interest
but other related kinases (left), rendering uncertain
the mechanisms of action of both the kinase of
interest and the inhibitor. If adding an ir-mutant
version of the kinase of interest in the continued
presence of inhibitor (right) restores cellular func-
tion, this validates the role of the kinase of interest
in the cellular process and as the physiologically
relevant target of the inhibitor.
(B–D) Aligning the ligand signature to insensitive
kinases predicts resistance. (B) Alignment of Cdk2
with the kinase domains of c-Abl and EGFR, with
the ligand signatures (Cdk2-NU6102, c-Abl-Im-
atinib, EGFR-Erlotinib) highlighted in yellow. (C)
Comparison of the c-Abl-Imatinib ligand signature
with kinases naturally less sensitive to Imatinib;
substitutions with respect to the c-Abl signature
are highlighted in red. Asterisks indicate that
binding energy is mainly due to main-chain atoms.
The row labeled ‘‘Kinase’’ indicates conservation
among all kinases (Hanks and Hunter, 1995),
where ‘‘o’’ represents a hydrophobic amino acid,
lowercase are nearly invariant and uppercase are
invariant residues; ‘‘-’’ indicates variable residues.
Domain indicates the position of the residue in
conserved kinase domains (Hanks and Hunter,
1995). The substitutions found at these positions in
Imatinib-resistant Abl mutants (Azam et al., 2003;
Bradeen et al., 2006) are shown on the bottom row.
(D) Comparison of the Cdk2-NU6102 ligand sig-
nature with related kinases naturally less sensitive
to NU6102, as in (C). Ki values were measured in
kinase assays using recombinant commercially
available complexes (human Cdk1 and Cdk2) or
complexes purified in our lab (Xenopus Cdk1,
Cdk2, and Cdk4). Numbers in square brackets
indicate published values. H, Human. X, Xenopus.
See also Figure S2.
(E) Spectrum of inhibitor resistance of Cdkmutants
against NU6102, RO-3306, and Purvalanol A.
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Cdk2 Chemical Biologypredict positions that, when substituted, can generate resistant
kinases.
We therefore applied this approach to Cdk2. The Cdk2-
NU6102 signature comprises 11 amino acids (Figures 2B, 2D,
and S2), and, unlike the Abl-Imatinib and EGFR-Erlotinib signa-1032 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 Elsevier Ltd All rights resetures, the gatekeeper residue is not
involved (Figure 2B). The Cdk2-NU6102
signature is identical between Xenopus
and human Cdk2. In related protein
kinases that are naturally less sensitive
to NU6102, 7 out of the 11 residues are
identical (Figure 2D). In Cdk1, which is
less sensitive to NU6102 than Cdk2 (see
above), only glutamine-85 is substituted
to methionine. Although the adjacent
residue asparagine-84 (Xenopus) or histi-
dine-84 (human) does not form part ofthe ligand signature, it might influence the orientation of Q85
and is serine in Cdk1. Second, lysine-89, which is predicted to
form transient hydrogen bonds with NU6102 (Heady et al.,
2006), is frequently divergent in kinases insensitive to NU6102.
Substituting K89 in Cdk2 with threonine, the equivalent residuerved
Table 2. Inhibitor Resistance and Cost to Enzymatic Efficiency of Mutant Cdk2 Alleles
WT K89D K89E
N84S
Q85M Q131E
K89D
Q131E
N84S
Q85M
K89D
N84S
Q85M
K89E
N84S
Q85M
Q131E
N84S
Q85M
K89D
Q131E
Km [ATP] (mM) 158 ± 15 226 ± 29 217 ± 31 93 ± 10 55 ± 4 118 ± 40 203 ± 21 92 ± 13 7 ± 1 141 ± 47
kcat (s
1) 3 1,000 440 ± 30 60 ± 4 110 ± 50 450 ± 42 141 ± 11 4 ± 1 320 ± 28 97 ± 12 35 ± 4 5 ± 5
kcat/Km [ATP] 2,800 280 520 4,900 260 33 1,600 1,100 5,000 36
Ki [NU6102] (nM) 500 ±
30
1,200 ±
140
1,200 ±
580
1,260 ±
250
810 ±
260
6,700 ±
2,000
8,600 ±
3,200
2,100 ±
570
860 ±
200
5,400 ±
1,500
Km [ATP]/
Ki [NU6102]
a
310 190 180 74 68 18 24 44 8 26
kcat. Ki [NU6102]/
Km [ATP]
a
1.40 0.32 0.61 6.1 2.07 0.23 13.5 2.2 4.3 0.19
Relative resistance
factor
1 0.23 0.43 4.3 1.48 0.19 9.6 1.6 3.1 0.16
All mutations were made in Xenopus Cdk2, which was purified with full-length Xenopus cyclin E and assayed in vitro with histone H1 and variable ATP
or NU6102 concentrations. Enzymatic efficiency is defined by kcat/Km, whereas Vmax is proportional to kcat. In all but one case (N84S-Q85M), one or
both of these parameters is decreased. kcat. Ki/Km provides a measure of the resistance of the kinase activity to inhibitor; this is divided by the value for
the wild-type to obtain the relative resistance factor.
aFractional standard errors of the ratios Km [ATP]/Ki [inhibitor] and kcat. Ki /Km are not shown because they are misleading: these are transformations of
two or more independent variables, so the fractional standard error values must be added to determine that of the ratio. However, in reality, the error
distribution is asymmetrical and cannot generate negative values for the mean. See also Table S1 for human complexes.
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Cdk2 Chemical Biologyin Cdk4, does not affect NU6102 affinity (Pratt et al., 2006), but
in this case the removal of a hydrogen bond formed by K89 is
likely to be canceled out, because burial of threonine within
a complex does not incur the desolvation penalty paid by K89.
However, reversing the charge of K89, as in ERK2, should be
energetically unfavorable by both maintaining the desolvation
penalty and preventing bond formation. Third, glutamine-131,
which forms nonpolar interactions with NU6102, is substituted
by serine in p38a and ERK2 and glutamate in Cdk4. The hy-
drogen bond with the ribose of ATP should be maintained in
these substitutions. Finally, leucine-134 is substituted by alanine
in p38a. Q85 and K89 do not interact with ATP in the crystal
structure (Figure S2C) (Russo et al., 1996), and although L134
forms nonpolar interactions with the purine moiety, these might
be retained by alanine.We thusmade the following substitutions:
N84S-Q85M, K89D, K89E, Q131E and L134A, and the combina-
tions K89D-Q131E, L134A-Q131E, N84S-Q85M-K89D, N84S-
Q85M-K89E, N84S-Q85M-Q131E and N84S-Q85M-K89D-
Q131E, with the aim of generating resistance to NU6102.
To perform restoration of function assays in the Xenopus
system, these alterations were made in Xenopus Cdk2, as it
has different kinetic parameters from human Cdk2 (Krasinska
et al., 2008). These Cdk2 mutant kinases were purified as active
complexes with full-length Xenopus cyclin E (see Experimental
Procedures). We first measured the kinetic parameters of each
complex to establish their catalytic efficiencies. Kinase activity
was undetectable for combinations containing the L134A substi-
tution, suggesting that L134 is essential for ATP binding in Cdk2.
The Km of most other mutant combinations were within a factor
of two of the wild-type, indicating that they retain close to normal
affinity for ATP, although Q131E decreased Km (increased ATP
affinity) by a factor of three (Table 2). Combining Q131E with
N84S-Q85M caused a 20-fold drop in Km (increase in ATP
affinity), suggesting that wild-type Cdk2 has not evolved tomaxi-Chemistry & Biology 19, 1028–mize this parameter, perhaps to avoid a penalty in catalysis. For
optimal catalysis, enzymes should favor binding of the transition
state intermediate rather than the primary substrate, and indeed
N84S-Q85M-Q131E resulted in more than a 10-fold drop in kcat,
as compared to a 3-fold decrease with Q131E alone. In other
words, increasing ATP affinity may be a mechanism of inhibitor
resistance, but it can reduce catalytic activity. K89 mutation
also caused a 4- to 7-fold decrease in kcat, but in combination
with N84S-Q85M, the kcat was restored, suggesting that small
changes in local environments of amino acid side chains not
involved in binding ATP can combine to affect catalysis.
The mutants N84S-Q85M, Q131E, N84S-Q85M-K89D, and
N84S-Q85M-Q131E all have catalytic efficiencies (kcat/Km) com-
parable to the wild-type enzyme. Interestingly, the kcat and cata-
lytic efficiency of the N84S-Q85Mmutant were even greater than
that of the wild-type enzyme. This substitution is part of the
natural sequence of Cdk1. Whether or not the enhanced effi-
ciency contributes to different functions of Cdk1 and Cdk2 is
an interesting question.
We next tested the affinity of the mutants for NU6102
and found that all had an increase in Ki corresponding to de-
creased affinity, with the combinations K89D-Q131E, N84S-
Q85M-K89D, and N84S-Q85M-K89D-Q131E showing a 10- to
17-fold rise in Ki (Table 2).
Perhaps the best way of assessing resistance that takes into
account inhibitor affinity, ATP affinity, and catalytic power, is to
consider the factor kcat. Ki/Km, that is proportional to catalytic
efficiencies in the presence of NU6102. Compared to the wild-
type enzyme, the N84S-Q85M and N84S-Q85M-K89D combi-
nations caused 4.3- and 9.6-fold increases in this factor, respec-
tively (Table 2; Figure 2E). This compares favorably with the c-Abl
Y253F mutation that causes phenotypic resistance to Imatinib,
and the Plk1 R136G BI2536-resistant mutant, that provoke
only modest (<4-fold) increases in IC50 values (Roumiantsev1040, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1033
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Figure 3. Rescue of DNA Replication in Cdk2-Inhibited Interphase
Xenopus Egg Extracts by ir-Cdk2 and Cdk1
(A) Modeling kinase activities of wild-type (WT) and ir-Cdk2 (SM, N84S-Q85M;
SMD, N84S-Q85M-K89D) and Cdk1 in extract conditions.
(B) The percentage of input DNA replicated was quantified by measuring
radioactive 33P-dCTP incorporation after 2 hr incubation. Extracts were
treated either with DMSO at 1% (vehicle) (Control) or 100 mM NU6102, either
alone or supplemented with ir-(N84S-Q85M-K89D) recombinant Xenopus
Cdk2-cyclin E, a 2-fold higher activity of WT Cdk2-cyclin E, or an equivalent
activity of Cdk1-cyclin A fusion protein. Error bars show standard error of the
mean (n = 8). *significantly different (p < 0.05).
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proportional to Ki/Km when Km is low with respect to ATP con-
centration, that is, within cells. The N84S-Q85M-K89D ir-Cdk2
mutant also demonstrates significant resistance against both
RO-3306 and Purvalanol A, showing that multiple inhibitor-resis-
tance can be achieved by mutation of these residues (Figure 2E).
Other mutants possess a different spectrum of inhibitor resis-
tance, demonstrating that it is possible to obtain mutants selec-
tively resistant to inhibitors.
Selective Cdk Inhibition and Restoration Demonstrates
the Limits of Redundancy of Cdks in DNA Replication
To see how activity of the N84S-Q85M-K89D ir-Cdk2 mutant
would compare with that of wild-type Xenopus Cdk2-cyclin E
and Cdk1-cyclin A at different NU6102 concentrations in extract
conditions, we performed mathematical modeling (Figure 3A).
NU6102-mediated inhibition of replication is maximal at about
100 mM (Figure 1C), and the around 40% of residual replication
appears to be Cdk1-dependent (Krasinska et al., 2008). At this
NU6102 concentration, the ir-Cdk2 mutant should retain about
33% of its activity, compared to about 3%–4% for the wild-
type, whereas Cdk1 should still retain about 52% activity (Fig-
ure 3A). To complement chemical inhibition and restore Cdk2
function, we introduced the ir-Cdk2 mutant at physiological
levels in 100 mM NU6102-treated Xenopus egg extracts. This is
predicted to generate total Cdk2 activity (endogenous plus ir
mutant) of about 37% of the original Cdk2 activity in the extract,
and it restored replication rates to about 74% (Figure 3B). This
level of replication is about the same as in the presence of
10 mM NU6102 but without recombinant proteins, where wild-
type Cdk2 is predicted to retain 30%–40% of its original activity
(Figures 1C, 1D, 1E, and 3A). Therefore, adding the ir mutant
caused an effective rescue of Cdk2 activity that agrees almost
perfectly with modeling predictions. Interestingly, adding extra
wild-type Cdk2 increased replication from 40% to around 50%
(Figure 3B). This is statistically significant (p < 0.05) and is equiv-
alent to replication at 50 mM NU6102 without exogenous Cdk2
(Figure 1D). At 50 mM NU6102, endogenous Cdk2 is predicted
to retain 7% of its original activity (Figures 1C, 1E, and 3A),
that is, double the activity predicted at 100 mM in the absence
of exogenous Cdk2 (Figure 3A). Thus, partial rescue by wild-
type Cdk2 is also in very good agreement with predictions and
is consistent with observations that depletion of the majority of
Cdk2 from an extract has only minor effects on DNA replication
rates (Krasinska et al., 2008). Strikingly, adding extra Cdk1-cy-
clin A protein could rescue replication as effectively as ir-Cdk2
(Figure 3B). In this case, where total Cdk1 activity is predicted
to be restored to normal levels, replication should rely essentially
on Cdk1 activity, as Cdk2 is inhibited. Modeling (Figure 1C)
shows that at 100 mM NU6102, over 80% of the residual com-
bined (Cdk1 + Cdk2) activity should be due to Cdk1. Increasing
Cdk1 activity by an equivalent amount would give a total (Cdk1 +
Cdk2) activity around that normally obtained with 20 mMNU6102
(Figure 1C), where replication is about 60%of control (Figure 1E).
That the rescue with Cdk1 is actually better than this suggests
that Cdk1-cyclin A activity may even be more effective than
Cdk2-cyclin E activity at promoting DNA replication. We con-
clude that Cdk2 activity is normally rate-limiting simply because
Cdk1 activity present in the extract is not high enough to support1034 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 Elthe extremely rapid replication, providing further support for the
quantitative model of Cdk control of the cell cycle.
Conformational Flexibility as an Important Determinant
of Inhibitor Binding
The above results show that selective resistance against
NU6102, RO-3306, and Purvalanol A can be achieved, depend-
ing on mutant combinations. RO-3306 is selective for Cdk1 and
NU6102 for Cdk2, but the Cdk-binding mechanism of RO-3306
is not known. Crystallization conditions for human Cdk2-cyclin
A are well characterized, so to compare how these two com-
pounds bind Cdks, we crystallized human Cdk2-cyclin A with
RO-3306 and NU6102. The latter structure has previously been
reported (Davies et al., 2002). Comparison of the structures
indeed suggests distinct binding modes of the two inhibitorssevier Ltd All rights reserved
Figure 4. Distinct Modes of Binding of Inhibitors with Different Cdk
Selectivity
Crystal structures of wild-type human Cdk2-cyclin A in complexes with AMP-
PNP, NU6102, and RO-3306 were solved and compared, and ATP cavity
modeling was performed.
(A) Both inhibitors cause a reorientation of the glycine rich loop reducing the
ATP cavity volume when compared to ATP, suggesting induced fit.
(B) Ligand-binding modes of Cdk2-cyclin A complexed with NU6102 (left; dark
green for the Cdk2 residues and yellow for NU6102) or RO-3306 (right; light
green for Cdk2 residues and dark blue for RO-3306). Residues lying within
a 8 A˚ radius of the ATP binding site ligand are displayed in ball-and-stick
representation. Hydrogen bonds are highlighted by a gray dashed line.
(C) Superposition of structures of WT human Cdk2-cyclin A with NU6102 and
RO-3306. See also Table S2 and Figures S4 and S5.
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specific inhibitors. With the glycine-rich loop folding around the
cavity, both molecules induce a reduction of the Cdk2 ATP-
binding pocket volume, and modeling of the cavity size reveals
a decrease from 603 A˚3 with a nonhydrolysable mimic of ATP
(adenosine 50-[b,g-imido]triphosphate [AMP-PNP]) to 581 and
481 A˚3 with RO-3306 and NU6102, respectively (calculated by
Pocket-Finder [Hendlich et al., 1997]). RO-3306 binding involves
a contraction from the C-terminal lobe and a concomitant expan-
sion to the exterior of the hinge region (Figure 4A). These struc-
tures highlight the intrinsic plasticity of the kinase and suggest
that induced fit might help to generate inhibitor specificity. As
previously published, NU6102 binding is mainly due to hydrogenChemistry & Biology 19, 1028–bonding with the hinge region and D86 (Figure 4B). The different
orientations of K88 and K89 from the published structure further
indicate that this region is flexible and reinforces the possibility of
dynamic interactions with the ligand (Heady et al., 2006) (Fig-
ure 4B). Interestingly, the C terminus of Cdk2 fits into a hydro-
philic pocket adjacent to H84, not seen in previous structures,
also implying dynamic flexibility. In contrast, RO-3306 forms
mainly hydrophobic interactions, between the quinoline ring
and the side chains of F82 and L134 and between the thiophene
ring and the glycine-rich loop (Figure 4B). Q131 side chain is also
oriented toward the thiophene ring. The quinoline group of RO-
3306 orients toward the hinge region but forms only a single
hydrogen bond with L83, whose main-chain carbonyl protrudes
into the solvent. This in turn causes the imidazole side chain of
H84 to reorient toward the C terminus, which can no longer fit
in the hydrophilic pocket and folds around the hinge region, al-
lowing interactions of H84 and Q85 with L296 and R297 side
chains of the selectivity region. Thus, a knock-on effect from
the hinge region creates distal effects with important conse-
quences for binding energy and potentially also substrate inter-
actions. Inhibitor-induced conformational changes have previ-
ously been seen with cAMP-dependent protein kinase (Prade
et al., 1997), suggesting that kinase active sites may generally
be flexible. Our results suggest that such conformational flexi-
bility might also contribute to inhibitor specificity. Interestingly,
mutations in N84 and Q85 in Xenopus Cdk2 have only marginal
effects on NU6102 and RO-3306 affinity but synergize strongly
with K89D mutation in reducing NU6102 (but not RO-3306)
affinity (Table 2). In contrast, K89D and Q131E mutations alone
strongly affect RO-3306 but not NU6102 affinity and are syner-
gistic; however, kinase activity of the K89D-Q131E mutant is
abolished (Table 2; Figure 2E).
Small Local Environment Changes Can Combine to
Affect Ligand Binding
We reasoned that not only are ir mutants useful tools to investi-
gate function but their study could reveal mechanisms of inhib-
itor resistance, which inmost kinases are very poorly understood
or unknown. To explore the structural effects of Cdk2 mutations
causing inhibitor resistance, we generated mutants in human
Cdk2 at the same positions as those we identified in the Xenopus
kinase and then cocrystallized wild-type and mutant Cdk2 in the
presence of AMP-PNP, NU6102, and RO-3306. For the human
mutant Cdk2-cyclin A complexes, the kinetics data (Table S1)
show qualitatively similar trends as with Xenopus Cdk2-cyclin
E. However, the catalytic efficiency is more strongly affected in
some mutants, implying a greater cost of developing resistance.
The different cyclins in these two complexes might account for
these differences because Cdk2-cyclin E has a lower affinity
for ATP and NU6102 than does Cdk2-cyclin A (Table 1).
In both human and Xenopus complexes, the Q131E mutation
strongly augments ATP affinity, which is largely responsible for
its NU6102 resistance. We therefore compared crystal struc-
tures of WT, Q131E, and H84S-Q85M-Q131E human Cdk2-cy-
clin A in complex with AMP-PNP and Mg2+. In the mutants, the
acidic side chain of Q131E reorients toward the AMP-PNP,
creating a weak electrostatic interaction that is strengthened in
the context of the triple mutant (Figure 5A). There is an overall
contraction of the ATP-binding site in the H84S-Q85M-Q131E1040, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1035
Figure 5. Structural Basis for Cdk Inhibitor
Resistance
(A) A first mechanism of resistance involves
increased ATP affinity of Cdk2 Q131E mutants.
Crystal structures of wild-type (dark green in ball-
and-stick representation), Q131E (cyan in ball-
and-stick representation), or H84S-Q85M-Q131E
(light green in ball-and-stick representation) hu-
man Cdk2-cyclin A in complex with AMP-PNP
(orange in ball-and-stick representation) and Mg2+
(represented by an apple green sphere) were
solved, and ATP was modeled in the electron
density map. Structural comparison of the ATP
binding site (only residues within an 8 A˚ radius of
the ATP molecule are displayed).
(B) A second mechanism of inhibitor resistance
in Cdk2 involves charge insulation. The crystal
structure of ir mutant human Cdk2-cyclin A in
complexes with NU6102 was solved and com-
pared. Residues (magenta for H84S-Q85M-K89D
Cdk2, yellow for NU6102) lying within a 8 A˚ radius
of the ATP binding site ligand are displayed in ball-
and-stick representation. Hydrogen bonds are
highlighted by a gray dashed line.
(C) Superposition of structures showing discrete
rearrangement of the ATP site residues. Cdk2
residues in ball-and-stick mode are colored in
dark green for WT and magenta for mutant,
NU6102 in yellow.
(D) Electrostatic surfaces of WT (left) and H84S-
Q85M-K89D mutant (right) human Cdk2-cyclin
A in complex with NU6102 computed by the
CHARMM-GUI (Jo et al., 2008). Negative charges
are highlighted in red and positive charges in blue.
See also Figures S3, S4, and S5 and Table S2.
Chemistry & Biology
Cdk2 Chemical Biologymutant, which has a nearly 6% decrease in the ATP-binding site
pocket volume. Coupled with shorter electrostatic interactions,
and a more polarized electrostatic surface (Figure S3), this
should contribute to the higher ATP affinity of the mutants.
The structure of the NU6102-resistant H84S-Q85M-K89D
mutant shows NU6102 binding in a slightly different orientation
to the wild-type, with the sulphonamide group moving closer
to D86 (Figures 5B and 5C). Because of the K89D substitution,
there is an excess of negative charge in the vicinity, which
appears to be reinforced by the Q85M mutation, whose in-
creased hydrophobicity may insulate against charge dispersion
(Figure 5D). The van der Waals interaction between the sulfon-
amide group and the aliphatic portion of K89 is reduced in the
mutant. The H84S-Q85M mutation again affects the C terminus,
abolishing electrostatic interactions but allowing hydrophobic
interactions of L298 with M85, which would be restricted with
H84. These structures show that amino acids not directly inter-
acting with the ligand can impact upon ligand binding, for
example, by acting as charge insulators or inducing reposition-
ing of distal amino acids, contributing to the global energetics
of the complex.
In all mutants, although the cavity volume oscillates between
491 and 556 A˚3, crystal structures show that the general RO-
3306 binding mode remains normal (Figure S4). The modified
electrostatic surfaces of the mutant have less impact on the
more hydrophobic binding of RO-3306 than on NU6102 binding1036 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 El(Figure S5). In WT Cdk2, Q131 packs against the thiophene
group of RO-3306, whereas in Q131E, K89D-Q131E, or H84S-
Q85M-Q131E structures with RO-3306, the glutamate group
adopts a different conformation (Figure S4), probably reducing
van der Waals interactions and explaining the effect of mutation
of this residue on RO-3306 affinity. Otherwise, the overall confor-
mations of the ATP binding site are similar in all mutants, showing
that mutations designed to confer resistance to NU6102 do not
greatly alter binding of an inhibitor with a different binding mech-
anism. These results suggest structural features that might be
used to develop secondary inhibitors active against mutants
resistant to a first inhibitor.DISCUSSION
In this study, we use an integrated chemical biology approach to
study how redundant Cdks control DNA replication. This also re-
vealed important information about Cdk biochemistry and struc-
tural features conferring susceptibility to inhibitors. Our main
findings, and their significance, can be summarized as follows.
1. The cyclin subunit modulates the affinity of the Cdk
complex for ATP, which in turn influences the efficiency
of chemical inhibition. Inhibitors can indeedbeselective for
Cdk1 (RO-3306), Cdk2 (NU6102), or inhibit both kinases
equally well (Purvalanol A). These observations are insevier Ltd All rights reserved
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functional experiments. Using these kinetic parameters,
we could mathematically model inhibition in a physiolog-
ical system in agreement with experimental results, sug-
gesting that total Cdk activity may be the main factor
determining efficiency of DNA replication.
2. It is possible to predict mutations generating inhibitor
resistance in kinases where the potential for resistance is
unknown. In both c-Abl and Cdk2, comparing the signa-
ture of amino acids energetically important for binding of
an inhibitor with the sequence of insensitive kinases allows
accurate prediction of mutations rendering a kinase inhib-
itor resistant, suggesting that it might be a useful general
approach. Inhibitor resistance can be achieved not only
by decreasing affinity for inhibitor but also by increasing
affinity for ATP. This is also true for the EGFR gatekeeper
mutation T790M, which confers resistance to gefitinib by
causing a 10-fold decrease in Km even though the muta-
tion does not affect affinity for the inhibitor (Yun et al.,
2008), suggesting that this increasing ATP affinity might
be a general mechanism of inhibitor resistance for eukary-
otic kinases. Moreover, we found that combining muta-
tions may be synergistic as, for example, the mutation
Q85M insulates the negative charge induced by the sub-
stitution K89D. An interesting and very recent paper (Bal-
zano et al., 2011) has found that mutating residues at
amino acid positions two and six C-terminal from the gate-
keeper residue, whichmap to the base of the hinge region,
can often induce inhibitor resistance in a variety of different
kinases. In our work, we also identify the hinge region as
important for conferring inhibitor resistance.
3. Chemical biology experiments, in combination with math-
ematical modeling, demonstrate that Cdk2 has a rate-
limiting role in DNA replication in Xenopus egg extracts
because of the relatively low Cdk1 activity in interphase
egg extracts. This resolves the discrepancy between
genetic experiments in somatic cells and in mice (Berthet
et al., 2003; Chung and Bunz, 2010; Hochegger et al.,
2007; Ortega et al., 2003), where Cdk2 is dispensable
for DNA replication, and biochemical experiments in
Xenopus, where Cdk2 is rate-limiting for DNA replication
(Fang and Newport, 1991; Krasinska et al., 2008). Why
then have embryonic systems evolved to rely on Cdk2?
One possibility is that it allows amuch higher Cdk2 activity
to be achieved, in order to promote more efficient repli-
cation origin firing required in embryonic development,
without the danger of provoking inappropriate entry into
mitosis, as Cdk2 is unable to promote mitosis onset even
when correctly expressed (Satyanarayana et al., 2008).
4. Whereas most mutations conferring a catalytic advantage
in the presence of an inhibitor impair catalysis in its ab-
sence, we identify some combinations that have normal
catalytic efficiencies in both conditions. This might be
important, as it is becoming accepted that clinical resis-
tance may develop as a result of selective pressure of
the therapy itself, which kills sensitive cells. This eliminates
their competitive advantage over resistant populations,
enabling the latter to proliferate (Gatenby, 2009). Using
Cdk inhibitors could also potentially favor growth of resis-Chemistry & Biology 19, 1028–tant populations.Most Cdk2mutations conferring inhibitor
resistance that we found have poorer kinetics in the
absence of inhibitor, that is, they incur a cost. However,
we identified several mutant combinations with apparently
normal kinetics. Knowledge of such kinetics may be
important in predicting responses in vivo, because non-
costly mutant alleles might be widely present in cancer
cell populations and might even explain poor primary
responses, whereas costly mutant alleles might only pre-
dominate after selection. Therefore, responses of the
system to external intervention can only be predicted
from knowledge of the basic parameters of the system
components.
5. Crystal structures ofwild-type andNU6102-resistant Cdk2
demonstrate that charge dispersion and small position
adjustments are important for ligand binding. Inhibitors
with different selectivity have distinct binding modes as
determined by X-ray crystallography. Substitutions can
create discrete effects that alter the total binding energy,
whichwould have been difficult to predict from the primary
structure or by bioinformatics approaches. The fact that
theRO-3306bindingmode is retained inNU6102-resistant
mutants raises the possibility of designing ligands that
should effectively, and perhaps even specifically, inhibit
these mutants. These might be of low toxicity to cells
harboring wild-type alleles and potentially provide a
solution to clinical NU6102 resistance.
Our results suggest a resolution for discrepancies in theories
of cell-cycle control by Cdks that may be due to the use of
different strategies. For example, Cdk1, Cdk2, and Cdk3 were
originally found to have nonredundant essential functions in
human cells by expression of dominant-negative constructs
(van den Heuvel and Harlow, 1993), yet depletion approaches
(Tetsu andMcCormick, 2003) and recent mouse knockouts (Ma-
lumbres andBarbacid, 2009) had challenged this view. However,
specific chemical inhibition of Cdk2 can arrest the cell cycle in
some conditions (Merrick et al., 2011). We favor the reasoning
that this is not due to a unique intrinsic ability of Cdk2 to promote
S-phase onset but rather that it is because inhibited Cdk2 can
still associate with cyclins A and E, sequestering them away
fromCdk1 and thus blocking essential functions of these cyclins.
Here, we can restore normal DNA replication rates using either ir-
Cdk2 or by increasing activity of the naturally NU6102-resistant
Cdk1 while maintaining Cdk2 inhibited. This allows us to con-
clude, by an approach independent of protein depletion, that
Cdk2 is the main physiological target of NU6102 during DNA
replication but that elevating Cdk1 activity can compensate for
loss of Cdk2 activity. Thus, we confirm that Cdk2 and Cdk1 do
not have major intrinsic differences in their ability to promote
DNA replication, supporting the quantitative model. Our results
also define mechanisms of kinase inhibitor resistance. This
may have more general relevance in the light of kinase inhibitor
use, and emerging resistance, in cancer therapy.SIGNIFICANCE
Cdk2 is involved in DNA replication and is a promising tar-
get for pharmacological inhibitors in cancer. However, by1040, August 24, 2012 ª2012 Elsevier Ltd All rights reserved 1037
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the related essential kinase Cdk1. Second, it is not clear
how to target Cdk2 selectively, as most Cdk2 inhibitors
also target Cdk1. Third, it is not known whether Cdks can
mutate to render them resistant to inhibitors, a potential
problem in cancer therapy. This work tackles all three ques-
tions. We present the structural and kinetic basis for Cdk2
inhibitor selectivity, and we propose an approach that can
be used to effectively design mutations conferring inhibitor
resistance. The principles of the approach are not limited
to kinase inhibitors and could in theory be used to study
any crystallized enzyme-ligand complex. Such mutants
can be used to distinguish redundant and nonredundant
cellular functions of an individual kinase because they do
not require protein depletion. Using this approach, we
show that Cdk2 is indeed rate-limiting for DNA replication
in Xenopus egg extracts, confirming it as a good cell cycle
target but that increasing Cdk1 activity can compensate
for inhibiting Cdk2. This resolves discrepancies in interpre-
tation of Cdk roles that are due to the use of different
systems and reinforces the quantitative model of cell-cycle
control by Cdk activity. Finally, structural and kinetic anal-
ysis of the mutant Cdk2 demonstrates molecular mecha-
nisms of inhibitor resistance, whichmay be important in vivo
and might also be applicable to other kinases involved in
cancer. These results may help in designing better, more
specific Cdk inhibitors for therapy, including compounds
that target resistant mutant alleles.
EXPERIMENTAL PROCEDURES
Ligand Signature Determination
Continuum electrostatics (Sheinerman et al., 2005) identified energetically
important residues of NU6102 binding based on the structure 1H1S. All calcu-
lations were performed as described (Sheinerman et al., 2005). The cumulative
error of electrostatic calculations is estimated to be s z 0.5 kcal/mol. The
residues with the electrostatic contributions to binding DGelec R 1 kcal/mol
are defined as being important electrostatically for the binding affinity. Simi-
larly, the residues with a nonpolar contribution DGnonpolar R 1 kcal/mol
are selected as those making important nonpolar contributions to binding. A
set of residues contributing significantly to binding either electrostatically
(DGelec R 1 kcal/mol) or hydrophobically (DGnonpolar R 1 kcal/mol), or both,
comprises the ligand signature for the Cdk2-NU6102 complex.
Enzyme Kinetics Modeling
Modeling was performed assuming Michaelis-Menten kinetics with different
inhibitor concentrations. Assumptions are that free ATP concentration is
1 mM, available inhibitor concentration equals applied inhibitor concentration,
and inhibition of each complex is independent.
Protein Kinase Expression
Recombinant Cdk complexes were generated by expression and purification
from Escherichia coli. For Xenopus Cdk2 complex, Cdk2 was expressed in the
cold-shock vector pCold-TF as a 6His-tagged trigger-factor fusion protein,
bicistronically with an IRES and yeast CAK1 to cotranslationally phosphorylate
and activate the Cdk. Full-length Xenopus cyclin E1 was expressed as a
6His-tagged trigger-factor fusion protein using pCold-TF. The complex was
purified as described in the Supplemental Experimental Procedures, and the
tags were cleaved off using TEV protease. The trigger factor and TEV protease
had neither influence on kinase assays nor on DNA replication in egg extracts.
Cdk1 was expressed and purified similarly to Cdk2, except that it was pro-
duced as a fusion protein with cyclin A, as described in the Supplemental
Experimental Procedures. For human complexes, the Cdk was produced1038 Chemistry & Biology 19, 1028–1040, August 24, 2012 ª2012 Elfrom a bicistronic vector of GST-human Cdk2 in pGEX6P-1 containing an
IRES and GST-CAK1. Untagged human cyclin A2 (residues 169–430) was ex-
pressed from pET21D. The complex was purified as described in the Supple-
mental Experimental Procedures.
Kinase Assays
Recombinant Xenopus Cdk2-cyclin E1 (see below) or commercially available
complexes (ProQinase) were used as indicated. Substrates were either RbCTF
peptide (ProQinase) (Cdk4) or histone H1 (all other complexes). Kinase assays
were performed as described in the Supplemental Experimental Procedures. A
minimum of three independent experiments was performed to determine
kinetic parameters, which were calculated using GraphPad Prism software.
Xenopus Egg Extracts and DNA Replication Assays
Interphase egg extracts were prepared as described previously (Krasinska
et al., 2008). For replication assays, extract aliquots were thawed and supplied
with cycloheximide (100 mg/ml), energy mix, 1,400 demembranated sperm
nuclei /ml, and 0.2 mCi/ml a33P-labeled dCTP. Where indicated, 1:100 dilutions
of NU6102 were added. DNA synthesis was measured from aliquots taken at
indicated time points, spotted onto glass fiber filters, precipitated in ice-cold
5% TCA, 2% pyrophosphate, washed three times in 5% TCA, dried, and
counted by scintillography.
Crystal Generation, X-Ray Data Collection and Processing,
Structure Solution, and Structure Refinement
T160-phosphorylated Cdk2-cyclin A complex solution (13 mg/ml) was incu-
bated with the desired ligand-containing solution (2 mM AMP-PNP or 0.5 to
1mMDMSO-dissolved inhibitor [NU6102 provided for crystallization purposes
by Dr. R. Griffin, University of Newcastle or RO-3306]), and crystals were
grown by hanging drop formation at 4C. The reservoir solution contained
0.6–0.8 M KCl, 0.9–1.2 M (NH4)2SO4, and 100 mM HEPES (pH 7.0). Crystals
were cryoprotected in 7 M sodium formate (with or without the addition of
AMP-PNP and MgCl2) before being frozen in liquid nitrogen. Data were
collected on a single crystal of each Cdk2/cyclin A/inhibitor complex at 100
K at either the ESRF (ID29 beamline) or Soleil Proxima1 beamline. Data pro-
cessing and integration were carried out using MOSFLM (Powell, 1999) and
SCALA (Evans, 2006). The structures were solved by molecular replacement
with MOLREP (Vagin and Teplyakov, 2000) using a well-refined structure of
Cdk2/cyclin A3 as the search model. Two Cdk2/cyclin A dimers were found
in the asymmetric unit. The presence of ligands was identified by inspection
of the Fourier difference electron density map, and the molecules were
modeled in the density. Rounds of manual model building in Coot (Emsley
and Cowtan, 2004) and refinement with Refmac (Murshudov et al., 1997)
were carried out until R and RFree factors did not improve. Addition of MgCl2
either in the crystallization solution or in the cryosolution was necessary to
observe AMP-PNP binding to Cdk2. The data collection and refinement statis-
tics are summarized in Table S2. Coordinates and structure factors for each of
the structures have been deposited in the Protein Data Bank under the acces-
sion code listed in Table S2.
Structure Analysis and Molecular Graphics
The kinase cavities were identified, and their volumes were evaluated by
Pocket-Finder (Hendlich et al., 1997). The electrostatic surfaces were calcu-
lated on the CHARMM-GUI (Jo et al., 2008). All the structural figures were
generated in Pymol (http://www.pymol.org).
SUPPLEMENTAL INFORMATION
Supplemental information includes five figures and two tables and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2012.06.015.
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